作者
Manuel Ramos-Casals, Oliver Lambotte, Marie Kostine, Leonard Calabrese, Maria Suarez-Almazor, Clifton Bingham, Timothy R Radstake, Chiara Baldini, Thierry Schaeverbeke, Jacques-Eric Gottenberg, Hendrik Schulze-Koops, Jan Leipe, Cassandra Calabrese, Pilar Brito-Zerón, Alejandra Flores-Chávez, Belchin Kostov, Soledad Retamozo, Gustavo Citera, Eva Aguilar, Michael Richter, Merav Lidar, Benjamin Fisher, Jean-Marie Michot, David Liew, Russell Buchanan, Marte Schrumpf-Heiberg, Philippe Guilpain, Debashish Danda, Peter Olsson, Yasunori Suzuki, Saadettin Kılıçkap, Gabriela Hernandez-Molina, Virginia Fernandes Moça Trevisani, Sonja Praprotnik, Ildiko Fanny Horváth, Naoto Azuma, Berkan Armagan, Munther Khamashta, Xavier Mariette
发表日期
2019/6/1
来源
Annals of the Rheumatic Diseases
卷号
78
期号
Suppl 2
页码范围
607-608
出版商
BMJ Publishing Group Ltd
简介
Background
The ImmunoCancer International Registry (ICIR) is a Big Data-Sharing multidisciplinary network composed by 39 specialists in Rheumatology, Internal Medicine, Immunology and Oncology from 18 countries focused on immune-related adverse events (irAEs) related to cancer immunotherapies (CIs).
Objectives
To analyse the worldwide scenario of irAEs associated with the use of CIs in this Century.
Methods
The first objective of the ICIR has been the development of a systematic literature review crossing CIs terms with immune diseases defined according to MedDRAVR 15.0.
Results
The cumulated number of cases per year of irAEs has increased exponentially, with 12,648 patients who developed 13,051 irAEs reported until Dec 31, 2018:
Combined CIs were used in 1962 (16%) patients, checkpoint inhibitors in 7099 (66%, overwhelmingly CTLA4 and PD1 inhibitors) and Tyrosine Kinase inhibitors in …
学术搜索中的文章
M Ramos-Casals, O Lambotte, M Kostine, L Calabrese… - 2019